跳至主要内容
临床试验/ITMCTR2200006076
ITMCTR2200006076尚未招募1 期

A double-blind randomized controlled trial of Qizhi Tongfeng Granule in the treatment of chronic refractory gout

Fangshan Hospital Affiliated to Beijing University of Chinese Medicine0 个研究点开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

性别
All

入选标准

  • (1) Voluntarily participate in the clinical study and sign the informed consent;
  • (2) It conforms to the diagnostic criteria of refractory chronic gout set by The Chinese Guidelines for the Diagnosis and Treatment of Hyperuricemia and Gout in 2019;
  • (3) Conforming to the criteria for waiting diagnosis of spleen deficiency, turbidity and stasis;
  • (4) No acute attack within 4 weeks;
  • (5) Between 18 and 75 years of age, regardless of gender

排除标准

  • (1) Secondary gout: gout caused by renal failure, diuretics, pyrazinamide, etc.;
  • (2) Having an allergic constitution and being known or suspected to be allergic to the test drug and its excipients;
  • (3) complicated or secondary chronic kidney disease (such as uric acid nephropathy);
  • (4) complicated with serious cardiovascular and cerebrovascular diseases, primary diseases of blood, liver and kidney system, or complicated with mental diseases;
  • (5) complicated with acute infectious diseases, active or delayed chronic hepatitis B, decompensated cirrhosis, active tuberculosis;
  • (6) Unstable vital signs, severe electrolyte disorder, or renal replacement therapy has been performed;
  • (7) Long-term use of other Traditional Chinese medicine preparations for more than 4 weeks with other diseases;
  • (8) pregnant women, breast-feeding women or women with recent pregnancy plans;
  • (9) Have participated in or are participating in other clinical trials within the last 3 months;
  • (10) The investigator considers it inappropriate to participate in this clinical trial.

研究者

发起方
Fangshan Hospital Affiliated to Beijing University of Chinese Medicine

相似试验